Search
bremelanotide (Vyleesi)
Indications:
- premenopausal women with acquired, generalized hypoactive sexual desire disorder
Contraindications:
- uncontrolled hypertension
- cardiovascular disease
- concurrent use of naltrexone for opioid or alcohol use disorder
Dosage:
- injection
- no more than one dose a day or 8 doses a month
- stop treatment at 8 weeks if no improvement in sexual desire or distress
Adverse effects:
- nausea often with 1st injection
- darkening of the gums & skin (1%)
- increased blood pressure that usually resolves within 12 hours
Mechanism of action:
- activates melanocortin receptors widely expressed in the brain
General
metabolic agent (metabolic modifier)
Database Correlations
PUBCHEM correlations
References
- FDA News Release. June 21, 2019
FDA approves new treatment for hypoactive sexual desire disorder
in premenopausal women.
https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-hypoactive-sexual-desire-disorder-premenopausal-women